Filing Analysis
Kairos Pharma, Ltd. has announced a 1-for-7 reverse stock split to be effective September 1, 2026. The split aims to consolidate outstanding shares and adjust the trading basis on the NYSE American.
🚩 Red Flags
- Reverse stock split (often used to maintain minimum bid price requirements for exchange listing).
📋 Key Facts
- Reverse stock split ratio is 1-for-7.
- Effective date for the split is September 1, 2026.
- The split will adjust the number of shares issuable upon exercise of warrants and RSUs and increase their exercise prices proportionately.
- No fractional shares will be issued; fractional shares will be rounded up to one full share.
- New CUSIP number for Common Stock: 48301N203.
- VStock Transfer LLC is acting as the exchange agent.
Kairos Pharma, Ltd. entered into an Investigator / Institution Initiated Research (IIR) Agreement with Bayer HealthCare Pharmaceuticals Inc. on July 16, 2026. Under the agreement, Bayer will provide radium for a study investigating the therapeutic activity of ENV-105 (carotuximab) in models of prostate cancer bone metastasis.
🚩 Red Flags
- The Company is solely responsible for financing the Study, meaning this is a supply agreement rather than a full co-development funding deal.
📋 Key Facts
- Agreement date: July 16, 2026
- Counterparty: Bayer HealthCare Pharmaceuticals Inc.
- Scope: Bayer provides radium for the Company's study on ENV-105 (carotuximab) and prostate cancer bone metastasis models.
- Company Obligations: Solely responsible for initiating, managing, and financing the Study; must provide final analysis/conclusions to Bayer within 6 months of completion.
- Control Provision: The Company must obtain prior written approval from Bayer before making any material changes to Study protocols.
Kairos Pharma, Ltd. issued a press release regarding interim safety data from its ongoing Phase 1 clinical trial for ENV-105 (Carotuximab) in combination with osimertinib for advanced EGFR-mutated non-small cell lung cancer.
📋 Key Facts
- Reported interim safety data for ENV-105 (Carotuximab) + osimertinib combination therapy.
- The trial targets patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC).
- Data pertains to an ongoing Phase 1 clinical trial.
Kairos Pharma Ltd. held its 2026 annual meeting where stockholders approved a significant amendment to the Certificate of Incorporation to authorize a reverse stock split with a ratio between 1:3 and 1:250.
🚩 Red Flags
- Approval of a reverse stock split (ratio up to 1:250) is often used to regain compliance with minimum bid price requirements for exchange listing.
- Significant dilution potential via the approved expansion and 'evergreen' provisions in the Equity Incentive Plan.
📋 Key Facts
- Annual Meeting held on June 29, 2026; 62.81% of eligible shares (13,450,506) were voted.
- Stockholders approved a reverse stock split ratio between 1:3 and 1:250.
- Four directors were elected to the Board for one-year terms: John S. Yu, Hyun W. Bae, Hansoo Michael Keyoung, and Rahul Sighvi.
- Weinberg & Company, P.A. was ratified as independent auditors for fiscal year ending Dec 31, 2026.
- Stockholders approved an increase of 5,000,000 shares to the 2023 Equity Incentive Plan and an 'evergreen' 5% annual increase provision.
Kairos Pharma, Ltd. issued a press release on June 4, 2026, summarizing the company's achievements for the first half of 2026 and outlining expected milestones for the remainder of the year.
📋 Key Facts
- The filing date is June 4, 2026.
- The company provided a summary of H1 2026 achievements.
- The company outlined key milestones expected by the end of 2026.
- The information was furnished as Exhibit 99.1 and is not deemed 'filed' under Section 18 of the Exchange Act.
Kairos Pharma, Ltd. issued a new investor presentation on May 18, 2026, for use at the LD Micro Invitational XVI conference. CEO John Yu will present updates regarding the company's clinical programs and partnering activities.
📋 Key Facts
- The report was filed on May 18, 2026, coinciding with the LD Micro Invitational XVI in Los Angeles.
- CEO John Yu is scheduled to provide updates on clinical programs and partnering activities.
- The investor presentation is furnished as Exhibit 99.1.
- The company is an emerging growth company listed on the NYSE American under the symbol KAPA.
Kairos Pharma entered into a binding term sheet to acquire 100% of the worldwide rights to CL-273, a pan EGFR small molecule inhibitor for lung cancer, from Celyn Therapeutics. The transaction involves significant equity issuance and future milestone payments.
🚩 Red Flags
- Significant dilution of 16.5% for existing shareholders.
- Substantial future cash/equity obligation of $15 million upon regulatory filing.
- The asset CL-273 is noted as being developed by Eilean Therapeutics, suggesting a potentially complex chain of ownership or licensing with Celyn.
📋 Key Facts
- Acquisition of 100% worldwide rights to CL-273, including IP, manufacturing, and regulatory rights.
- Consideration includes issuing shares representing 16.5% of the Company on a fully diluted basis.
- A $15 million milestone payment is due upon FDA NDA/BLA submission, payable in cash and shares.
- A 2% royalty on U.S. net revenues will be paid for the life of the applicable IP.
- Closing is subject to shareholder approval and potential NYSE American approval.
Kairos Pharma, Ltd. has entered into a letter of intent with Celyn Therapeutics, Inc. to acquire worldwide rights to two clinical-stage oncology assets targeting non-small cell lung cancers (NSCLC). The assets include CL-273, a pre-IND pan-EGFR inhibitor, and CL-741, a Phase 1-ready c-MET kinase inhibitor.
🚩 Red Flags
- The filing does not disclose the financial terms, purchase price, or potential dilution associated with the acquisition.
- A letter of intent is generally non-binding, and there is no guarantee the transaction will close on the proposed terms.
📋 Key Facts
- Letter of Intent (LOI) signed on February 26, 2026, with Celyn Therapeutics, Inc.
- Acquisition targets worldwide rights to two oncology assets: CL-273 and CL-741.
- CL-273 is described as a pre-IND, reversible, wild-type-sparing pan-EGFR inhibitor.
- CL-741 is described as a Phase 1-ready, orally available type IIb c-MET kinase inhibitor.
- Both assets are specifically designed to target non-small cell lung cancers (NSCLC).
Kairos Pharma, Ltd. announced the approval of $950,000 in Restricted Stock Units (RSUs) and $227,500 in cash bonuses for executives and directors. The grants are intended to incentivize service through October 2026.
🚩 Red Flags
- Significant equity compensation for insiders (CEO/CSO/CFO) may lead to future dilution.
- Accelerated vesting upon 'change in control' is a standard but notable feature of executive packages.
📋 Key Facts
- Aggregate RSU grant value: $950,000 based on a per share price of $1.31.
- Total cash bonuses approved for executives: $227,500 for fiscal year 2024 performance.
- RSUs vest in full on October 8, 2026, subject to continuous service.
- CEO John S. Yu received the largest portion: 190,840 RSUs ($250k) and an $87,500 cash bonus.
- All unvested RSUs vest immediately upon a change in control.
Kairos Pharma, Ltd. has entered into two novation agreements to transfer patent licenses and supply rights from its wholly-owned subsidiary, Enviro Therapeutics, Inc., directly to the parent company. Additionally, the company announced it will present Phase 2 clinical data at the ESMO Congress in Berlin.
🚩 Red Flags
- Retroactive effective date (April 17, 2025) for the Cedars Novation Agreement may indicate a restructuring of debt or liabilities previously held by the subsidiary.
- The transfer of all liabilities from a wholly-owned subsidiary to the parent company can sometimes be used to consolidate obligations or clean up subsidiary balance sheets.
📋 Key Facts
- Entered into 'Cedars Novation Agreement' with Cedars-Sinai Medical Center, effective retroactively as of April 17, 2025.
- The Cedars agreement transfers exclusive licenses for two patents: one regarding mitochondrial/genomic DNA depletion and another regarding Endoglin Antagonism.
- Entered into 'Tracon Novation Agreement' with Tracon Pharmaceuticals, Inc., transferring rights to TRC105 and CD105 technologies from Enviro to Kairos.
- Kairos will present Phase 2 study data for apalutamide + carotuximab in advanced castration-resistant prostate cancer at the ESMO Congress (Oct 7–21, 2025).
- The novation agreements relieve the subsidiary, Enviro Therapeutics, Inc., of all liabilities and obligations related to these licenses.
Kairos Pharma, Ltd. announced positive efficacy data from its Phase 2 clinical trial of ENV105 (carotuximab) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The company is hosting a virtual Key Opinion Leader (KOL) event to discuss these findings.
📋 Key Facts
- Announced positive efficacy data from Phase 2 clinical trial of ENV105 (carotuximab).
- Target indication: metastatic castration-resistant prostate cancer (mCRPC).
- Scheduled a virtual KOL event for September 18, 2025, at 5 p.m. ET to discuss data.
- The filing includes a press release and a slide presentation as exhibits.
Kairos Pharma, Ltd. announced a Key Opinion Leader (KOL) event scheduled for September 18, 2025. The event will focus on discussing interim efficacy results from the Phase 2 trial of its lead candidate, ENV105, for advanced prostate cancer.
📋 Key Facts
- Event Date: September 18, 2025, at 5 p.m. ET / 2 p.m. PT.
- Topic: Discussion of interim efficacy results from Phase 2 trial of ENV105.
- Indication: Advanced prostate cancer.
- Lead Candidate: ENV105.
Kairos Pharma, Ltd. announced its participation in the upcoming World Lung Cancer Conference (September 6-9, 2025) to present initial Phase 1 data for ENV105 in non-small cell lung cancer.
📋 Key Facts
- Company will present initial Phase 1 data of ENV105 at the World Lung Cancer Conference.
- Presentation is scheduled for September 6-9, 2025, in Barcelona, Spain.
- The presentation will be delivered by Principal Investigator Dr. Karen Reckamp.
- Data pertains to non-small cell lung cancer (NSCLC) applications.
Kairos Pharma announced positive interim safety results from its Phase 2 clinical trial of ENV-105 (carotuximab) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The data from the first ten patients showed no dose-limiting toxicities or unexpected adverse events.
📋 Key Facts
- Interim safety analysis conducted on the first 10 enrolled patients in Phase 2 trial of ENV-105.
- ENV-105 is a first-in-class CD105 antagonist being tested in combination with apalutamide.
- No dose-limiting toxicities (DLTs) or unexpected adverse events reported to date.
- No Grade 3 or 4 toxicities observed in the interim cohort.
- Side effects were reported as manageable with standard supportive care.
Kairos Pharma, Ltd. entered into a one-year services agreement with Barretto Pacific Corporation for investor relations and public information dissemination. Additionally, the company held its annual meeting where directors were elected and auditors were ratified.
🚩 Red Flags
- Approval to issue >20% of common stock below 'minimum price' (Section 713 compliance) suggests potential dilution pressure or capital needs.
- Engagement of an IR firm for $170k/year is a standard micro-cap expense but often indicates a need to boost market visibility.
📋 Key Facts
- Entered into a Services Agreement with Barretto Pacific Corporation (BPC) on June 10, 2025.
- The agreement covers IR services including disseminating public info, communicating with the brokerage/investment community, and identifying investor conferences.
- Service fee is $170,000 for a one-year term, payable in monthly increments.
- Four directors (John S. Yu, Hyun W. Bae, Hansoo Michael Keyoung, and Rahul Sighvi) were elected to the board.
- Stockholders ratified Weinberg & Company, P.A. as independent auditors for FY 2025.
- Stockholders approved the issuance of common stock in excess of 20% at a price below 'minimum price' per NYSE American rules.
Kairos Pharma, Ltd. announced that CEO Dr. John Yu will present clinical data for the investigational small molecule GITR ligand agonist KROS101 at the ASCO 2025 Annual Meeting.
📋 Key Facts
- Event date: June 3, 2025
- CEO Dr. John Yu to participate in the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting.
- The presentation will highlight data on KROS101, an investigational small molecule GITR ligand agonist.
- Meeting location: McCormick Place, Chicago, IL.
Kairos Pharma, Ltd. has dismissed its independent auditor, Marcum LLP, and appointed Weinberg and Company, P.A. as its new registered public accounting firm effective April 23, 2025.
🚩 Red Flags
- Auditor change combined with existing material weaknesses in internal control over financial reporting (FY23 and FY24).
- Historical Going Concern Opinion issued by the previous auditor for the fiscal year ended Dec 31, 2023.
- Material weaknesses in internal controls reported in recent annual filings.
📋 Key Facts
- Dismissed Marcum LLP as the independent registered public accounting firm on April 23, 2025.
- Appointed Weinberg and Company, P.A. to serve as the new auditor for upcoming 10-Q and 10-K filings.
- The company reported no disagreements with Marcum LLP regarding accounting principles or auditing procedures.
- Material weaknesses in internal control over financial reporting were disclosed for fiscal years 2023 and 2024.
- Marcum's audit report for the year ended December 31, 2023, contained a 'Going Concern Opinion'.
Kairos Pharma, Ltd. issued an 8-K to furnish a letter from CEO Dr. John Yu providing updates on the clinical trials for lead product candidate ENV105 and business plans for the current year.
📋 Key Facts
- CEO Dr. John Yu provided a stockholder update via a formal letter.
- The update focuses on the clinical trial progress of the company's lead product candidate, ENV105.
- The filing includes an overview of business plans for the 2025 fiscal year.
Kairos Pharma, Ltd. announced a peer-reviewed publication in 'Drug Resistance Updates' regarding a potential breakthrough for treating EGFR-mutant non-small cell lung cancer (NSCLC). The study suggests that CD105 blockade may restore sensitivity to osimertinib in drug-resistant patients.
📋 Key Facts
- Publication released on March 20, 2025, in 'Drug Resistance Updates'.
- The research focuses on the role of CD105 (endoglin) in mediating resistance to osimertinib.
- Findings indicate that CD105 expression is upregulated as a mechanism of therapy resistance in NSCLC patients.
- Study title: 'CD105 blockade restores osimertinib sensitivity in drug-resistant EGFR-mutant non-small cell lung cancer'.
Kairos Pharma, Ltd. issued an 8-K to announce the presentation of preclinical data for its investigational compounds KROS 101 and KROS 401 at the AACR Immuno-Oncology conference.
📋 Key Facts
- Presented preclinical data on KROS 101 (GITR agonist) in melanoma and glioblastoma models.
- Presented preclinical data on KROS 401 (peptide inhibitor for macrophages) in glioma animal models.
- Presentation occurred at the American Association for Cancer Research Immuno-Oncology conference (Feb 23-26, 2025).
- The filing includes a press release as Exhibit 99.1.
Kairos Pharma, Ltd. announced that its leadership presented preclinical data for its KROS101 candidate at the AACR-JCA Joint Conference held in Maui, Hawaii.
📋 Key Facts
- The company presented preclinical data on KROS101, a glutocorticoid-induced tumor necrosis factor receptor agonist.
- Presentation occurred during the plenary session of the 13th AACR-JCA Joint Conference (Feb 1–5, 2025).
- Presenters included CEO Dr. John S. Yu and VP of R&D Dr. Ramachandran Murali.
Kairos Pharma, Ltd. closed a $3.4975 million PIPE offering consisting of 2,500,000 pre-funded units involving warrants to purchase common stock. The deal includes significant warrant coverage and requires the company to file a resale registration statement within 15 days.
🚩 Red Flags
- Significant warrant overhang: The common warrants allow the purchase of an additional 3,750,000 shares (1.5x the units), which could lead to substantial dilution.
- Pre-funded warrants at $0.001 per share effectively act as immediate equity issuance upon exercise, creating significant downward pressure.
- The inclusion of a '19.99% shareholder approval' clause suggests the transaction may trigger anti-dilution or beneficial ownership thresholds common in highly dilutive micro-cap financing.
📋 Key Facts
- Closed sale of 2,500,000 Pre-Funded Units for $3,497,500 on January 16, 2025.
- Each unit contains a pre-funded warrant to purchase one share at $0.001 and a common warrant to purchase 1.5 shares at $1.40 per share.
- Amended agreement includes a shareholder approval requirement for issuing >19.99% of common stock.
- Placement agents (Boustead Securities, LLC and D. Boral Capital LLC) received an 8% cash commission plus warrants for 175,000 shares at $1.40 per share.
- Company must file a resale registration statement within 15 days of closing.
Kairos Pharma, Ltd. entered into a Securities Purchase Agreement to raise $3.5 million in gross proceeds through the sale of Common Units and Pre-Funded Units to accredited investors via a PIPE offering.
🚩 Red Flags
- Significant dilution potential due to the issuance of 2.5 million common units plus warrants (1.5x coverage per unit).
- Pre-funded warrants with an extremely low exercise price ($0.001) effectively act as immediate equity, leading to rapid dilution.
- The offering is a PIPE (Private Investment in Public Equity), often used by micro-caps facing liquidity constraints.
📋 Key Facts
- Total aggregate gross proceeds: $3.5 million (before fees).
- Sale of 2,500,000 Common Units at $1.40 per unit.
- Common Units include one Common Share and one purchase warrant to buy 1.5 Common Shares.
- Pre-Funded Units priced at $1.399 per unit; includes a Pre-Funded Warrant with an exercise price of $0.001.
- Common Warrants have an exercise price of $1.40 and are exercisable six months from issuance.
- The company is required to file a registration statement within 15 days of closing.
- Lock-up agreements for officers, directors, and >10% stockholders for 90 days.
Kairos Pharma, Ltd. announced the resignation of Dr. Rosemary Mazanet from its Board of Directors and the simultaneous appointment of Dr. Rahul Singhvi to the Board.
📋 Key Facts
- Dr. Rosemary Mazanet resigned effective upon the appointment of a replacement; stated reason was personal reasons, not disagreement with company operations.
- Dr. Rahul Singhvi appointed as Director, Audit Committee member, Chair of Compensation Committee, and Chair of Nominating and Corporate Governance Committee.
- Dr. Singhvi is cofounder of Resilience (National Resilience, Inc.) and former CEO of Novavax, Inc.
- Compensation for Dr. Singhvi includes an annual cash fee of $50,000 and a grant of $50,000 in Restricted Stock Units (RSUs) vesting over three years.
Kairos Pharma, Ltd. announced its approval to dual-list its common stock on the Upstream market (a MERJ Exchange platform). Trading on this additional venue is scheduled to commence on November 26, 2024.
📋 Key Facts
- Company approved for dual listing on Upstream (MERJ Exchange market/global securities trading app).
- Trading on Upstream is expected to begin November 26, 2024, at 10:00 a.m. ET.
- The ticker symbol will remain 'KAPA'.
- The move is intended to access a global investor base and enhance liquidity/price discovery.
Kairos Pharma, Ltd. announced that CEO Dr. John S. Yu will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit and released an updated corporate presentation.
📋 Key Facts
- CEO Dr. John S. Yu to speak with Jason McCarthy, Ph.D. (Maxim Group) at the 2024 Maxim Healthcare Virtual Summit.
- The summit is scheduled for October 15-17, 2024.
- Company updated its corporate presentation (Investor Deck) on October 10, 2024.
- Information provided under Item 8.01 is furnished but not considered 'filed' for liability purposes.
Kairos Pharma, Ltd. entered into a 24-month consulting agreement with Cross Current Capital LLC and Alan Masley to provide financial, business development, and capital markets advisory services.
🚩 Red Flags
- Potential related-party transaction involving an 'Advisor' (Alan Masley) and Cross Current Capital LLC.
- Significant equity issuance ($500k) to a consultant which may lead to future dilution for existing shareholders.
- The scope of services is broad, including 'auditor introductions' and 'investment banking introductions,' which can sometimes signal a company in need of urgent restructuring or financing.
📋 Key Facts
- Agreement date: October 1, 2024
- Term: 24 months, with a potential 12-month extension
- Cash compensation: $200,000
- Equity compensation: Restricted shares of common stock valued at $500,000 (issuable under the 2023 Equity Incentive Plan)
- Equity vesting: Shares vest six months after issuance
- Services include: Valuation analysis, investor relations/marketing, M&A canvassing, and capital markets advisory.
Kairos Pharma, Ltd. entered into two significant service agreements on September 23, 2024: an advertising agreement with CEO.CA Technologies and a strategic advisory agreement with Belair Capital Advisors Inc. The latter involves both cash payments and the issuance of restricted stock units to a long-term investor/advisor.
🚩 Red Flags
- Related-party transaction: Belair Capital Advisors Inc. is noted as a 'long-term investor and advisor,' suggesting potential conflicts of interest in the terms of the advisory agreement.
- Equity issuance for services: The use of 50,000 RSUs to compensate an advisor/investor can lead to dilution and may be viewed as a form of compensation for existing stakeholders.
📋 Key Facts
- Entered into a one-year advisory and consulting services agreement with CEO.CA Technologies Ltd. for $250,000.
- CEO.CA services include strategic news placement, interviews, monthly analytics, and video launch.
- Entered into a 12-month Strategic Advisory Agreement with Belair Capital Advisors Inc. (BCA).
- The BCA agreement includes a $365,000 fee and the issuance of 50,000 restricted stock units (RSUs) vesting in six months.
- Belair Capital Advisors Inc. is identified as a long-term investor and advisor to the Company.
Kairos Pharma, Ltd. entered into a Bioassay Services Agreement with PreCheck Health Services, Inc. to support clinical trials for carotuximab (ENV105). The agreement involves biomarker screening and the development of a companion diagnostic for lung and prostate cancer patients.
📋 Key Facts
- Agreement date: September 20, 2024
- Counterparty: PreCheck Health Services, Inc. (Florida-based)
- Total contract value: $900,000 for laboratory services
- Purpose: Biomarker screening and companion diagnostic development using the SolidTumorCheck+ platform
- Clinical trial support: NCT05401110 (Phase 1 lung cancer) and NCT05534646 (Phase 2 prostate cancer)
Kairos Pharma, Ltd. has successfully closed its Initial Public Offering (IPO), pricing 1,550,000 shares at $4.00 per share. The offering resulted in gross proceeds of $6.2 million before expenses and included the issuance of warrants to underwriters.
🚩 Red Flags
- Issuance of warrants at a premium to the IPO price ($4.80 vs $4.00) is common but represents potential future dilution.
📋 Key Facts
- IPO Price: $4.00 per share
- Shares Sold: 1,550,000 common shares
- Gross Proceeds: $6,200,000 (before discounts and expenses)
- Underwriter Option: 45-day option to purchase up to 232,500 additional shares
- Warrants Issued: Two warrants for a total of 108,500 shares (54,250 each) to Boustead Securities, LLC and EF Hutton LLC
- Warrant Exercise Price: $4.80 per share (120% of IPO price)
- Warrant Expiration/Exercise Window: Commencing March 16, 2025, ending September 17, 2029